Business, energy, technology, markets and global industry news from Business News Today

United States Food and Drug Administration

PharmaDeviceNews United States Food and Drug Administration
A clinician reviews lymphoma treatment data as Genmab and AbbVie clarify that the Phase 3 EPCORE DLBCL-1 trial missed its sole United States overall survival endpoint despite a progression-free survival benefit for epcoritamab. Representative image.
Pharma & Biotech

Genmab and AbbVie clarify EPCORE DLBCL-1 missed sole US overall survival endpoint

Genmab and AbbVie clarify that EPCORE DLBCL-1 missed its sole US overall survival endpoint despite a PFS benefit for epcoritamab.

Read More
Summit Therapeutics enters a pivotal phase for ivonescimab as the oncology developer deploys its $690.7 million cash position toward an upcoming FDA decision, HARMONi-3 data and an expanding late-stage lung cancer programme. Representative image.
Pharma & Biotech

Summit Therapeutics has $690.7m, but one November FDA decision now towers over everything

Summit Therapeutics ends Q2 with $690.7m as ivonescimab approaches an FDA decision and pivotal HARMONi-3 data in late 2026.

Read More
Representative image: A monitored sleep study and oral medication illustrate Incannex Healthcare’s DReAMzz Phase 2 screening program as the company refines IHL-42X dosing before a planned Phase 3 obstructive sleep apnea trial.
Pharma & Biotech

Incannex Healthcare begins DReAMzz screening to refine IHL-42X dosing before Phase 3 sleep apnea trial

Incannex Healthcare begins DReAMzz screening to select an IHL-42X dose before Phase 3. Read what the sleep apnea study must prove.

Read More
Representative image: Clinical researchers review cardiopulmonary data and oral therapy options as Inhibikase Therapeutics advances IKT-001 in a pivotal Phase 3 trial for pulmonary arterial hypertension following FDA Orphan Drug Designation.
Pharma & Biotech

Inhibikase Therapeutics gains FDA orphan status for IKT-001 as pivotal PAH trial advances

Inhibikase Therapeutics wins FDA orphan status for IKT-001 as its pivotal PAH trial tests whether a prodrug can improve imatinib tolerability.

Read More
Verastem Oncology advances its VS-7375 development programme as the TARGET-D 202 Phase 2 trial begins evaluating the investigational KRAS G12D inhibitor in previously treated advanced non-small cell lung cancer. Representative image.
Pharma & Biotech

Verastem has entered the KRAS G12D lung cancer race, but can VS-7375 close the evidence gap?

Verastem begins TARGET-D 202, testing 900 mg VS-7375 in previously treated KRAS G12D NSCLC, including a brain metastases cohort.

Read More
Affinia Therapeutics’ AFTX-201 gene therapy is advancing through the UPBEAT trial after receiving FDA Orphan Drug designation for BAG3-associated dilated cardiomyopathy. Representative image.
Pharma & Biotech

Affinia Therapeutics advances AFTX-201 gene therapy for BAG3 dilated cardiomyopathy

Affinia Therapeutics gains FDA orphan status for AFTX-201 as the UPBEAT trial tests gene therapy for BAG3 dilated cardiomyopathy.

Read More
TopGum eye health gummy combines 10 mg lutein with 2 mg zeaxanthin
Pharma & Biotech

Can TopGum turn brain and eye health into the next major gummy growth category?

TopGum is targeting cognition and eye health with new gummies, but evidence, claim discipline and brand adoption will decide commercial impact.

Read More
American Heart Association AI report suggests Ultromics EchoGo could support earlier HFpEF detection by bringing artificial intelligence into routine echocardiography workflows. Representative image.
Medical Devices & Diagnostics

Could Ultromics EchoGo improve early detection of heart failure with preserved ejection fraction?

Ultromics’ EchoGo model suggests earlier HFpEF detection, but prospective evidence will decide whether hospitals realize the projected gains.

Read More
D&D Pharmatech’s zabopegdutide Phase 2 study showed rapid reductions in liver fat and stiffness in patients with MASLD and MASH, strengthening the case for late-stage clinical development. Representative image.
Pharma & Biotech

D&D Pharmatech’s MASH candidate gains credibility as Phase 2 findings enter peer review

Peer-reviewed Phase 2 data link zabopegdutide to rapid liver fat and stiffness reductions, while Phase 3 validation remains the decisive test.

Read More
Automated cell therapy manufacturing could help Cellares and Papillon Therapeutics advance PPL-001 toward clinical development for Friedreich’s ataxia. Representative image.
Pharma & Biotech

Can Cellares automation move Papillon’s PPL-001 closer to a Friedreich’s ataxia trial?

Cellares will automate PPL-001 manufacturing for Friedreich’s ataxia, but IND-enabling work and human evidence remain ahead.

Read More